Data as of Dec 19
| +0.44 / +4.88%|
The 7 analysts offering 12-month price forecasts for Halozyme Therapeutics Inc have a median target of 12.00, with a high estimate of 24.00 and a low estimate of 5.00. The median estimate represents a +26.85% increase from the last price of 9.46.
The current consensus among 8 polled investment analysts is to Buy stock in Halozyme Therapeutics Inc. This rating has held steady since December, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.